This CPB has been revised to state that (i) leuprolide is considered medically necessary for the prevention of heavy uterine bleeding in pre-menopausal women during chemotherapy and for the treatment of women with dysfunctional uterine bleeding when other pharmacotherapies (e.g., non-steroidal anti-inflammatory drugs and estrogen-progestin contraceptives) have failed, (ii) leuprolide is considered medically necessary toreduce anemiaprior to fibroid surgery; and (iii) leuprolide is considered experimental and investigational for the treatment of parotid gland cancer, uterine cancer, benign prostatic hyperplasia, irritable bowel syndrome, catamenial pneumothorax, premature ovarian failure, stuttering, andamenorrhea induction prior to bone marrow transplant.

This CPB is revised to state that Goserelin (Zoladex) is considered medically necessary for precocious puberty and for dysfunctional uterine bleeding when criteria are met. This CPB is revised to state that Goserelin is considered experimental and investigational for invasive ductal breast cancer and premature ovarian failure secondary to chemotherapy.

This CPB is revised to state that triptorelin is considered medically necessary for the following indications: 1) true (central) precocious puberty; 2) non-atypical endometrial hyperplasia; 3) endometriosis; and 4) fibrocystic breast disease. 

This CPB is revised to state that degarelix is contraindicated and considered not medically necessary for persons with hypersensitivity to degarelix. This CPB is revised to state that degarelix is considered experimental and investigational for colon cancer.